|
|
|
| home > white papers > Planning the Execution of a Viral Clearance Study - Eurofins BioPharma Product Testing |
|
|
 WHITE PAPERS |
|
Eurofins BioPharma Product Testing
|
|
Planning the Execution of a Viral Clearance Study
|
|
Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Prince Helps Sustainable Pharma Packaging Pioneers Woolcool Celebrate 10th Anniversary
Ground-breaking sustainable pharma packaging firm Woolcool celebrated a decade of innovation with a visit by HRH The Prince of Wales.
More info >> |
|
 |
White Papers |
 |
|
Environmental Factors in Data Centres
Dycem
In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiña of Secure Techincal Rooms.
More info >> |
|
 |
Industry Events |
 |
ELRIG Drug Discovery 2019 – Looking Back to the Future
5-6 November 2019, ACC, Liverpool
Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at
ACC in Liverpool.
This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions
assessing how we got to where we are now and setting the challenges for discovering the
drugs of the future. These will be followed by cutting edge talks and examples of new
directions in drug discovery.
Our scientific programme will feature over 40 world-class speakers with 6 main session
tracks. In partnership with key academic and charitable groups, we will also run joint
disease and biology-oriented tracks focusing on the basic sciences that underpin
successful drug discovery.
More info >> |
|
|
|
